Aminopyridines for symptomatic treatment in multiple sclerosis
Evidence SummariesLevel of Evidence = D
Despite some positive results in small trials, no reliable conclusion can be made on the efficacy of aminopyridines for symptoms of multiple sclerosis.
A Cochrane review 1 included 5 studies with a total of 144 subjects. Four studies assessed the efficacy of 4-aminopyridine (AP) versus placebo, one compared 3,4-aminopyridine (DAP) with active placebo. The median quality score was 3 (range 2 - 5). Of the 144 treated patients, there were six major adverse effects, including acute encephalopathy and seizures. Muscle strength by manual muscle testing (29 patients on aminopyridines improving versus four during placebo, OR 14.5, 95% CI 4.7 - 43.7), ambulation (9 vs. none), and EDSS score (13 vs none) favoured the test drugs. 47 of 136 people with MS (35%) felt improved when receiving the study drug, against 7 (5%) on placebo (OR 9.7, 95% CI 4.3 - 22.0).
Comment: The quality of evidence is downgraded by potential reporting bias (no data could be obtained from three unpublished trials involving more than 300 patients), and severe study limitations (In all but one trial the primary endpoint was not specified, and detailed outcome was only reported on endpoints found to be statistically significant).
1. Solari A, Uitdehaag B, Giuliani G et al. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2002;(4):CD001330. [PMID:12804404].
Copyright © 2017 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.